Girindus, a service provider to the pharmaceutical industry and a leading manufacturer of therapeutic oligonucleotides, is pleased to announce today that it has signed a Commercial Collaboration Agreement with RiboTask, a leading small-scale provider of oligonucleotides for use in research and development, during the Girindus Leadership in Oligonucleotides Symposium (GLOS) in Cincinnati, Ohio, USA.
Under the terms of the agreement, RiboTask, a Denmark based company founded by Prof. Jesper Wengel and Suzy Lena, Chief Executive Officer of RiboTask, will gain access to the worldwide sales and marketing team of Girindus, and Girindus through the collaboration with RiboTask will have the ability to offer its customers seamless manufacture of a wide variety of oligonucleotides from the mg quantity to commercial kg quantities.
“Prof. Wengel, Chairman of the Board of RiboTask, has long been recognized as one of the leaders in the oligonucleotide field” stated Dr. Mark Laskovics, President and Chief Operating Officer of Girindus America Inc.. “And RiboTask has been built into a world-class organization to provide a range of oligonucleotides, particularly oligonucleotides possessing complex sequences. We are delighted that our two organizations will work together to provide the best possible solution for our customers.”
“We have seen in Girindus the technical and financial staying power to be the pre-eminent force in the oligonucleotide field,” stated Prof. Wengel. “We are delighted to enter into a partner relationship with Girindus!”
To learn more, please see Girindus.com, RiboTask.com or call Girindus at +1 513.679.3031 or RiboTask at +45 40 97 36 82.
Contacts:
Ralf Penner
Investor Relations & Public Relations
Girindus
AG, 51427 Bergisch Gladbach
T: +49 - (0)2204 - 926 - 900
F:
+49 - (0)2204 - 926 - 990
rpenner@girindus.com